Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exploring the signalling alteration between GBM8401 and GBM8401 supplemented with siINTS9

ABSTRACT: To investigate the changes of the transcriptome and relevent signalling between control and siINTS9 treated glioblastoma cell line,GBM8401.

ORGANISM(S): Mus musculus

PROVIDER: GSE233640 | GEO | 2023/06/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Exploring the Mechanism of Adjuvant Treatment of Glioblas-toma Using Temozolomide and Metformin

Project description:To investigate the changes of the transcriptome and relevent signalling between control and metformin treated glioblastoma cell line.

2022-07-26 | GSE208773 | GEO

Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma

Project description:To investigate the changes of the transcriptome and relevent signalling between control and siAUP1 treated glioblastoma cell line, U87MG.

2023-03-24 | GSE227721 | GEO

Exploring the signalling alteration between GBM8401 and GBM8401 supplemented with siINTS9

Project description:Exploring the signalling alteration between GBM8401 and GBM8401 supplemented with siINTS9

| PRJNA977064 | ENA

Wireless Electrical-Molecular Quantum Signalling for Cancer Cell Induced Death

Project description:To investigate the effect of electric fileds on the electrical-molecular signalling, we performed transcriptomic analysis on a sample of glioblastoma cells and healthy cortical astrocytes. Qiagen perform the RNA seq analysis of samples, to interrogate the effect of the of the bioelectronic communication tool on gene expression and regulation.

2023-06-01 | GSE233380 | GEO

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Project description:This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

| 2091475 | ecrin-mdr-crc

Collective signalling drives rapid jumping between cell states

Project description:Collective signalling drives rapid jumping between cell states

| PRJNA909293 | ENA

TWEAK/Fn14 signalling in Breast Cancer [cell line hiChIP]

Project description:TWEAK/Fn14 signalling in Breast Cancer [cell line hiChIP]

| PRJNA966125 | ENA

miR-483 overexpression in human sarcoma cell line MHH-ES-1.

Project description:miRNA abnormalities are increasingly relevent to cancer development, We used microarrays to detail the global programme of gene expression upon miR-483 overexpression in sarcoma cell line MHH-ES-1.

2013-12-31 | GSE50980 | GEO

Wnt signalling in colon cancer

Project description:Hypothesis and proof of concept: Our hypothesis is that increase in cellular iron import proteins (TfR1, DMT1) occur early in the adenoma-carcinoma sequence through mutations in APC and lead to cellular iron loading. As demonstrated in our previous work the effects of this iron loading is to mediate increased Wnt signalling resulting in c-myc induction. This in turn serves to increase the expression of iron import proteins (TfR1, DMT1) and decrease the expression of iron export (ferroportin [FPN]) and storage (ferritin) proteins. Such a hypothesis explains how Wnt signalling controls iron metabolism and ensures that there is adequate cellular iron for ATP generation and cellular proliferation. Experimental design: To test such a hypothesis we aim to prospectively collect the following colorectal tissue from patients attending for colonoscopy: 1. Normal colonic mucosa in patients with no colorectal pathology (n = 30) 2. Polyps and matched normal colon (n = 30) 3. Colorectal cancers and matched normal colon (n = 30) We also intend to collect serum and urine from the following patient groups: 4. Normal colonoscopy (n = 30) 5. Colorectal adenomas (n = 30) 6. Colorectal cancers (n = 30) Primary outcome(s): Measured at baseline, using the expression of proteins in the tissue and serum to detect the cellular and systemic iron transport proteins. The techniques used will include mass spectrometry, western blotting, real time PCR and immunohistochemistry.

| 2416626 | ecrin-mdr-crc

Human Glioblastoma Cell Line Secretome LC-MS/MS

Project description:To investigate the effect of glioblastoma secretome in activating tau pathology, Glioblastoma cell line secretome were prefractionated with gel filtration chromatography. Secretome analyzed by LC-MS/MS and identified targets using PSM count quantitation.

2018-07-16 | PXD007969 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data